Indian shares edge higher; lenders gain on Moody's upgrade

Published 09-04-2015, 12:15 pm
Updated 09-04-2015, 12:21 pm
© Reuters.

* BSE index up 0.1 pct; NSE index rises 0.2 pct

* Healthcare stocks fall

MUMBAI, April 9 (Reuters) - Indian shares were up on Thursday, rising for the fifth straight session and heading towards the highest close in three weeks, as lenders such as ICICI Bank ICBK.NS gained after rating agency Moody's upgraded India's sovereign ratings outlook.

Moody's revised India's sovereign ratings outlook to "positive" from "stable" on Thursday as it expected actions by policymakers to enhance the country's economic strength in the medium term. ID:nL4N0X61EL

A firm trend across the region also helped. Asian stocks rose extending the previous session's gains, while the dollar drew support from minutes of the Federal Reserve's last meeting showing the U.S. central bank was still on course to hike interest rates this year. MKTS/GLOB

"The ratings (outlook) upgrade will give more comfort for foreign investors and also attract more capital. Our fiscal deficit situation is under control and global investors are comfortable with that. The market undercurrent is positive," said Deven Choksey, managing director, KR Choksey Securities.

The benchmark BSE index .BSESN was up 0.11 percent at 28,740.71, while the broader NSE index .NSEI gained 0.17 percent to 8,729.30.

Lenders gained with the Bank Nifty index .NSEBANK of the NSE adding 1.8 percent after the ratings upgrade. The key banking sub-index is down 7.2 pct since Jan-end on concerns over valuations and expected delay in earnings recovery. ID:nL4N0X61NK

ICICI Bank ICBK.NS gained 1.6 percent, State Bank of India SBI.NS added 0.9 percent and HDFC Bank HDBK.NS was up 1.3 percent.

Broader gains were however capped as healthcare stocks fell with Sun Pharmaceutical Industries SUN.NS falling 2.7 percent after Bank of America (NYSE:BAC) Merrill Lynch (BoFA-ML) downgraded several pharma stocks. ID:nL4N0X61XB

BoFA-ML downgraded Sun Pharma to "underperform" from "buy", while it cut Lupin Ltd LUPN.NS amd Cadila Healthcare CADI.NS to "neutral" from "buy". Lupin and Cadila were down 2.9 percent and 1.3 percent, respectively.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.